Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJiMB21: Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
NCT05535166Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Dec 2022
- Primary completion
- Jul 2035
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of methotrexate, Cisplatin micelle injection (HA132), vincristine sulfate liposome injection, cyclophosphamide, carboplatin and 2 more in medulloblastoma (5 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Progression-Free Survival up to 7 years, Intelligence Quotient and 2 more. Started Dec 2022; status: recruiting.
02
Drugs
methotrexateCisplatin micelle injection (HA132)vincristine sulfate liposome injectioncyclophosphamidecarboplatin
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT05535166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535166.